Unicycive Therapeutics
UNCY
20 hedge funds and large institutions have $24.6M invested in Unicycive Therapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 14 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
17.04% less ownership
Funds ownership: 57.73% → 40.69% (-17%)
29% less capital invested
Capital invested by funds: $34.5M → $24.6M (-$9.83M)
31% less funds holding
Funds holding: 29 → 20 (-9)
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3M |
| 2 |
JP Morgan Chase
New York
|
+$134K |
| 3 |
Renaissance Technologies
New York
|
+$72.9K |
| 4 |
Lazard Asset Management
New York
|
+$71.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$2.35M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.86M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.39M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.07M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.01M |
UNCY Hedge Fund Activity: Q2 2025 in Review
20 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q2 2025, worth a combined $24.6M — down 29% from $34.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of UNCY and 5 opened new positions — a net loss of 9 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $3M. The largest seller was Walleye Capital, exiting entirely with an estimated $2.35M sold.
- 20 institutional investors held Unicycive Therapeutics (UNCY) as of Q2 2025, down from 29 in Q1 2025.
- Funds reported $24.6M of Unicycive Therapeutics stock for Q2 2025, down 29% quarter-over-quarter.
- 5 funds opened new Unicycive Therapeutics positions in Q2 2025 and 14 closed out, a net change of -9 holders.
- The largest Unicycive Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $3M added.
- The largest Unicycive Therapeutics seller in Q2 2025 was Walleye Capital, an estimated $2.35M sold.
Based on aggregated 13F filings for Q2 2025.